IGM Biosciences IncChange company Symbol lookupSelect an option...IGMS IGM Biosciences IncICGL Image Chain Group Limited IncHUSIF Nicola Mining IncSO Southern CoERC Wells Fargo Multi-Sector Income FundASG Liberty All-Star GrowthARPO Aerpio Pharmaceuticals IncAMRQQ Alta Mesa Resources IncXAIR Beyond Air IncUSA Liberty All-Star EquityGo
IGM Biosciences Inc is a biotechnology company engaged in the development of engineered IgM antibodies for the treatment of cancer patients. It has developed IgM antibody technology platform that is particularly well suited for developing T cell engagers, receptor cross-linking agonists and targeted cytokines. The Company’s lead product candidates are IGM-2323: CD20 x CD3 and Death Receptor 5 (DR5). Its IgM platform enables to create a broad pipeline of product candidates. The Company is also conducting research and discovery programs on CD3 T cell engaging antibodies; T cell stimulating antibodies, including antibodies that target T cell stimulatory members of the TNFrSF; and antibodies that are intended to deliver IL-15 to a target to enhance cancer immune responses while limiting systemic toxicity. Its product pipelines also include CD20 x CD3, CD123 x CD3, CD38 x CD3, solid tumor target x CD3 programs, OX40 and glucocorticoid-induced TNFr-related protein (GITR).
|
|
|
|
|
Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.
Options are not suitable for all investors as the special risks inherent to options trading may
expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.
Copyright © 2019. All rights reserved.